Genolution

Genolution Total Assets

The Total Assets of Genolution (225220.KQ) as of Nov 11, 2026 is 93.79 B KRW. In the previous year, Total Assets was 106.45 B KRW — a change of -11.90% (lower).

Total Assets

93.79 BKRW

YoY

-11.90%

Last updated:

Total Assets of Genolution is 2025 93.79 B KRW. Total Assets of Genolution was 2024 106.45 B KRW. It decreases by -11.90% lower compared to the previous year.

The Genolution Total Assets history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Total Assets
Date
Total Assets
Jan 1, 2018
11.10 B KRW
Jan 1, 2019
13.43 B KRW
Jan 1, 2020
83.77 B KRW
Jan 1, 2021
94.94 B KRW
Jan 1, 2022
114.45 B KRW
Jan 1, 2023
113.44 B KRW
Jan 1, 2024
106.45 B KRW
Jan 1, 2025
93.79 B KRW
The Genolution Total Assets history
YEARTotal AssetsYoY
93.79 BKRW-11.90%
106.45 BKRW-6.16%
113.44 BKRW-0.89%
114.45 BKRW+20.55%
94.94 BKRW+13.33%
83.77 BKRW+523.86%
13.43 BKRW+21.01%
11.10 BKRW+135.83%
4.71 BKRW+17.78%
3.99 BKRW—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Genolution Stock analysis

What does Genolution do? Genolution Inc develops automated nucleic acid extraction devices, nucleic acid extraction reagents, and molecular diagnostic products. The company also offers ribonucleic acid interference services. Its products are distributed domestically and internationally, serving customers in the biotechnology and healthcare sectors. The firm generates revenue through the sale of these products and services to research institutions, laboratories, and healthcare providers. The company's core offerings include nucleic acid extractors, reagents, and diagnostic products, which are used in molecular biology and medical diagnostics. Genolution Inc targets biotech firms, hospitals, and research facilities as key buyers of its technology. Its domestic market presence complements its international distribution channels. Genolution Inc's business model relies on selling its automated extraction devices and reagents to customers requiring efficient nucleic acid processing solutions. The company's molecular diagnostic products cater to healthcare applications, while its ribonucleic acid interference services support advanced research needs. Revenue streams are derived from both product sales and service contracts within the biotechnology industry. Genolution is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Genolution stock

Total Assets of Genolution is 93.79 B KRW in 2025.

Total Assets of Genolution changed from 106.45 B KRW to 93.79 B KRW, representing a -11.90% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Total Assets Genolution since 2006 – with annual values, charts, and detailed analysis.

Total assets represent everything a company owns, including cash, inventory, property, and intangible assets. It is a key measure of a company's size and resource base.

Total Assets's KRW is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Total Assets's Genolution historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Genolution

All Key Metrics — Genolution